Cytek Biosciences downgraded by TD Cowen with a new price target
$CTKB
Biotechnology: Laboratory Analytical Instruments
Industrials
TD Cowen downgraded Cytek Biosciences from Buy to Hold and set a new price target of $4.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/9/2025 | $4.00 | Buy → Hold | TD Cowen |
| 1/31/2025 | $7.00 → $4.50 | Buy → Sell | Goldman |
| 12/14/2023 | $9.00 | Overweight | Stephens |
| 7/19/2023 | Mkt Perform | Raymond James | |
| 2/15/2022 | $27.00 → $18.00 | Equal-Weight | Morgan Stanley |
| 1/6/2022 | $20.00 | Overweight | Piper Sandler |
| 10/15/2021 | Outperform | Cowen | |
| 8/17/2021 | Outperform | Cowen |
FREMONT, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences. UBS Precision Medicine Summit in Dana Point, CAPanel discussion: New Dimensions in Proteomics and Cellular Research on Thursday, August 14, 2025, at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time Wells Fargo Healthcare Conference in Boston, MAParticipating in investor 1x1 meetings on Thursday, September 4, 2025 Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NYFireside chat on September 10, 2025, at 7:00 a.m. Pacific Time /10:00 a.m. Eastern Time
FREMONT, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2025. Second Quarter Highlights Total revenue for the second quarter of 2025 was $45.6 million, representing a 2% decrease compared to the second quarter of 2024Expanded to a total installed base of 3,295 Cytek instruments, adding 146 units in the second quarter of 2025, and representing 3% unit growth of Cytek FSP® instruments compared to the second quarter of 2024Launched the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on
FREMONT, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next generati
TD Cowen downgraded Cytek Biosciences from Buy to Hold and set a new price target of $4.00
Goldman downgraded Cytek Biosciences from Buy to Sell and set a new price target of $4.50 from $7.00 previously
Stephens initiated coverage of Cytek Biosciences with a rating of Overweight and set a new price target of $9.00
10-Q - Cytek Biosciences, Inc. (0001831915) (Filer)
8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
SCHEDULE 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)
4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25
FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure. During his tenure, Williams played key roles in the company's growth, spearheading initiatives that improved operational processes and paving the way for Cytek's future success. His leadership has been integral to enhancing the company's ef
Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlook FREMONT, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB) today announced that William (Bill) McCombe has been appointed chief financial officer of the company effective immediately. McCombe brings experience as a public company CFO at both large scale, and smaller, high growth technology companies. He was CFO at Velo3D, a leader in metal 3D printing systems for the aerospace and other industries, CFO at HZO, a leader in delivering protective nano coatings for electronics, and EVP and CFO at Maxar Technologies, a multi-billion-
FREMONT, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2025. Second Quarter Highlights Total revenue for the second quarter of 2025 was $45.6 million, representing a 2% decrease compared to the second quarter of 2024Expanded to a total installed base of 3,295 Cytek instruments, adding 146 units in the second quarter of 2025, and representing 3% unit growth of Cytek FSP® instruments compared to the second quarter of 2024Launched the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on
FREMONT, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next generati
FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. First Quarter Highlights Total revenue for the first quarter of 2025 was $41.5 million, representing a 7.6% decrease compared to the first quarter of 2024Expanded to a total installed base of 3,149 Cytek instruments, including the Amnis® and Guava® instruments shipped since the acquisition of the product lines in February 2023, adding 115 units in the first quarter of 2025Commenced operations in Singapore to access low-cost manufacturing, increa
SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)
SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)
SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)